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INTRODUCTION:  
The oral route is considered as the most promising route 
of drug delivery. Effective oral drug delivery may 
depend upon the factors such as gastric several 
physiological limitations such as variable 
gastrointestinal transit, because of variable gastric 
emptying leading to non-uniform absorption profiles, 
incomplete drug release and shorter residence time of 
the dosage form in the stomach. This leads to 
incomplete absorption of drug shaving absorption 
window especially in the upper part of the small 
intestine, as once the drug passes down the absorption 
site, the remaining quantity goes unabsorbed. The 
Gastric emptying of dosage forms in humans factors 
because of which wide inter and are affected by several 
intra-subject variations are observed
1
. Since many drugs 
are well absorbed in the upper part of the 
gastrointestinal tract, such high vari-ability may lead to 
non-uniform absorption and makes the bioavailability 
unpredictable. Hence a beneficial delivery system would 
be one which possesses the ability to control and 
prolong the gastric emptying time and can deliver drugs 
in higher concentrations to the absorption site (i.e. upper 
part of the small intestine). Metformin HCl is an orally 
administered biguanide derivative widely used in the 
treatment of non-insulin dependent diabetes mellitus. It 
improves the glycemic control by enhancing insulin 
sensitivity in liver and muscles. Metformin also has 
beneficial effect on several cardiovascular risk factors 
such as dyslipidemia, elevated plasma-plasminogen 
activator inhibitor, other fibrinolytic abnormalities, and 
hyper insulenimia, and insulin resisance
2. 
Oral 
administration is the most convenient and preferred 
means of any drug delivery to the systematic circulation. 
Oral controlled release drug delivery have recently been 
of increasing interest in pharmaceutical field to achieve 
improved therapeutic advantages, such as ease of dosing 
administration, patient compliance and flexibility in 
formulation. Drugs that are easily absorbed from 
gastrointestinal tract (GIT) and have short half-lives are 
eliminated quickly from the systemic circulation. 
Frequent dosing of these drugs is required to achieve 
suitable therapeutic activity. To avoid this limitation, the 
development of oral sustained-controlled release 
formulations is an attempt to release the drug slowly 
into the gastrointestinal tract (GIT) and maintain an 
effective drug concentration in the systemic circulation 
for a long time. 
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ABSTRACT 
The aim present investigation is Formulation and Evaluation of Effervescent Floating Tablets of antidiabetic drug. Gastric 
retention are such systems, which increase the gastric retention time of the dosage forms at the stomach and upper part of the 
small intestine and suitable for the drug having site-specific absorption from the above sites. The Metformin HCl an orally 
administered biguanide of  BCS class-3 High solubility and low permeability, which is widely use in the management of and 
the type-II diabetes, is an oral anti- hyperglycemic agent, shows incomplete absorption from the gastrointestinal tract and from 
the gastrointestinal track and absolute bioavailability is 50-60%with relatively short plasma half-life of 1.5-4.5 hours. It was 
using different polymers studying of deferent factors affecting the floating behavior of the prepare tablets was of our goals and 
important target in this part. Gastro-retentive tablets of Metformin HCl were prepared by wet granulation method using HPMC 
K200M (Hydroxylpropyl methyl cellulose) micro crystalline cellulose PH 101, sodium bicarbonate, HPMC K100 (LV), 
Magnesium stearate, colloidal silicon dioxide. In this formulation HPMC K 200 M was using different concentration. The 
Gastro-retentive tablet of Metformin HCl was evaluation of compression blend Angle of repose, Bulk density, tapped density, 
Drug compressibility study, Drug release rate, floating lag time etc. Result of our present study suggests that gastro-retentive 
tablets of Metformin HCl can be successfully designed to develop sustained release drug delivery which can reduce dosing 
frequency 
Keywords: Effervescent system, gas generating system, gastro retentive drug delivery system, sustained drug release, 
Metformin hydrochloride 
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After oral administration, such a drug delivery would be 
retained in the stomach and release the drug in a 
controlled manner, so that the drug could be supplied 
continuously to its absorption sites in the 
gastrointestinal tract (GIT)
3
. These drug delivery 
systems suffer from mainly two adversities: the short 
gastric retention time (GRT) and unpredictable short 
gastric emptying time (GET), which can result in 
incomplete drug release from the dosage form in the 
absorption zone (stomach or upper part of small 
intestine) leading to diminished efficacy of administered 
dose
4
.
 
 
MATERIAL AND METHODS 
Table 1: List of various chemical/regents used in project work 
Sr.No Ingredient Source 
1 Metformin HCl Biocon limited 
2 Microcrystalline cellulose (Avicel PH 101) FMC Biopolymer 
3 Methocel K 200 M(HPMC) Colorcon 
4 Cabopol 971 P Colorcon 
5 Povidone K-30 BASF 
6 Methocel K 100 LV(HPMC) Colorcon 
7  Methocel K 100 M (HPMC) Colorcon 
8 Sodium bicarbonate Merck 
9 Synpro Magnesium stearate Ferro Industries 
10 Colloidal silicon dioxide (Aerosil 200 Pharma) Evonik industries AG 
11 Eudragit
®
 RL/PO Evonik 
12 Eudragit
®
  RL/PO Evonik 
13 Tri ethyl citrate  Vertellus 
14 Talc Signet 
15 Isopropyl alcohol Sri tirumala Chemical 
16 Acetone Avantor 
17 Acetonitrile Avantor 
18 HCL Sigma-Aldrich 
 
Table 2: List of Equipment used for the study 
Sr.No Equipment’s Manufacturer Model No 
1 Weighing balance Sartorius GPA5202 
2 Mechanical stirrer Remi Motors 5MHL PLU 
3 V-cone blender Chamunda CPM VB-50 
4 Mini Tablet Compression machine Kambert KMP-D8-08 
5 Portable Hardness tester Electrolab EH-01 
6 Automated Tablet Friabilator Electrolab EF-2W 
7 Vernier Caliper Mitutoyo CD-8”CSX 
8 Moisture analyser Sartorius MA150 
9 Tap density tester Electrolab ETD-1020 
10 Electromagnetic sieve shaker Electoral ENS-8 PLUS 
11 Rapid Mixer granulator Kevin HSMG-10 
12 Dissolution test  apparatus  Electrolab EDT-08LX 
13 Differential scanning calorimetry  Tzero
®
 DSC Q2000 (TA Instruments, 
14 Quadra-Co-Mill Gansons Quadr U-5 
15 High performance liquid Chromatography (HPLC) Waters and Agilent Alliance and 1260 
16 FTIR Spectrophotometer Perkin Elmer ------- 
17 Nuclear Magnetic Resonance Bruker  AV300 
18 Powder X-ray diffraction  Rigaku Ultima -------- 
19 Oven Thermolab T00001000S 
20 Stability Chamber Newtronic DCM-30 
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Procedure of pre-optimization study 
Preparation of tablets by wet granulation technique 
Floating matrix tablets containing of Metformin HCl 
were prepared using wet granulation method using 
HPMC K 100 M, K 200 M and carbopol 971 P as 
polymer.  All ingredients and d drug weight individually 
passed through sieve no 30, mixed and granulated with 
10% solution of  PVP K 30 in water. The wet mass was 
passed through the sieve no 16 and dried rapid dryer at 
30°C for 25min at 30cfm to control a final LOD of 
about NMT 2.0% w/w. Dried granules were passed 
through the sieves no 40G using Ganson’s Co-Mill and 
were mixed with weight quantity of sodium bicarbonate, 
lubricated with magnesium stearate and glidant colloidal 
silicon dioxide. 
Compression force was kept constant throughout the 
study. Compression was carried out for final blend by 
using CADMAC 16 x 9.5 mm oval shaped with  logo 
deposed on upper punch (D tooling). 
 
Table 3: Parameters in the RMG-(HSMG) 
Sr.no Parameters Time (Min) Impeller (rpm) Chopper (rpm) 
1 Dry Mix 10 500 NR 
2 Binder Addition 1 500 NR 
3 Kneading 1 500 1000 
 
Table 4: Composition of floating tablets of Metformin HCl  
Sr.No Ingredients Formula (mg/tab) 
1 Metformin HCl F1 F2* F3 F4 F5 
500 500 500 500 500 
2 HPMC K 100 M 100 100 100 --- --- 
3 HPMC K 200 CR --- --- --- 130 180 
4 Corbopol 941 P 32 32 22     --- --- 
5 Micro crystalline cellulose pH 101 37 24 34 46 44 
 Binder      
6 PVP-30K 10 10 10 10 --- 
7 HPMC K 100 LV --- --- --- --- 10 
Extra granular Ingredients      
8 Sodium bi carbonate 7 20 50 50 50 
9 Colloidal silicon dioxide 7 7 7 7 8 
10 Magnesium Stearate NF 7 7 7 7 8 
Tablet Weight: 700 700 730 750 800 
* Coating formulation no F2 (10%) 
 
Table 5: Coating composition (10%) formulation no F2 
S.NO. INGREDIENT WEIGHT ( gm) 
1 Eudragit RL/PO 11.84 
2 Eudragit RS/PO 30.33 
3 TEC 4.04 
4 Talc 20.22 
5 IPA 201.64 
6 Acetone 146.65 
7 Water 18.33 
 
Coating procedure: 
All ingredients were accurately weighted, Mixed 
manually desired quantity of Acetone and water, further 
added weighed quantity of TEC, stirrer for about 45 
minutes by using mechanical stirrer and mixed weighed 
quantity of Talc in to above prepared solution stir for 
about 20 minutes by using mechanical stirrer (Coating 
solution-1). Mixed weighed quantity of Eudragit 
RL/PO and Eudragit RS/PO in to Isopropyl alcohol, stir 
for about 30 minutes by using mechanical stirrer 
(Coating solution-2). Mixed slowly coating solution-1 
to coating solution-2 to prepare final coating solution 
and coating of formulation (F2) was done by using fully 
automatic pan coater ACG Coating QUEST-TC. 
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Procedure of Optimization Studies 
Doe optimization by 3
2
 central composite designs: 
The project leads to a method for preparing an extended 
release tablet formulation of 500mg Metformin HCl. A 
unique blend of matrix system was used as a base for 
retarded release of drug. Two different grades of 
hydroxypropylmethyl cellulose (HPMC K100 LV and 
HPMC K 200 M) were mixed in different ratio to obtain 
a suitable matrix system for achieving the extended 
release profile of the said Metformin HCl. There are two 
independent variables and three responses in the 
formulation designing process. A 3
2
 central composite 
design was employed for the purpose. Table 6: depicts 
the detailed composition of formulations prepared as per 
the optimization design.  
 
Table 6: Independent Variables and Different Levels Selected for 3
2
 Central Composite Design  
Std RUN Factor 1 
A: HPMC K 100 LV 
(mg) 
Factor 2 
B: HPMC K 200 LV 
(mg) 
Response 1 
Q1 % 
Response 2 
Q4 % 
Response 3 
Q10 % 
12 1 12.50 150.00 32 69 100 
9 2 12.50 150.00 32 69 100 
6 3 20.00 150.00 31 64 100 
1 4 5.00 80.00 34 68 92 
2 5 20.00 80.00 33 66 93 
5 6 5.00 150.00 31 64 92 
8 7 12.50 220.00 28 62 89 
13 8 12.50 150.00 28 69 100 
11 9 12.50 150.00 28 69 100 
10 10 12.50 150.00 28 69 100 
4 11 20.00 220.00 27 50 90 
7 12 12.50 80.00 31 67 100 
3 13 5.00 220.00 31 66 98 
 
Table 7: Composition of floating tablets of Metformin HCl  
Sr.No Ingredient Formulation Code (mg/tab) 
 
1 
 
Metformin HCl 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
500 500 500 500 500 500 500 500 500 
2 HPMC K 200 M 80 150 220 80 150 220 80 150 220 
3 MCC PH 100 169 99 29 161.5 91.5 21.5 154 84 14 
 Binder          
4 HPMC K 100 LV 5 5 5 12.5 12.5 12.5 20 20 20 
 
Extra granular 
ingredients 
         
5 Sodium bicarbonate 50 50 50 50 50 50 50 50 50 
6 
Colloidal silicon 
dioxide 
8 8 8 8 8 8 8 8 8 
7 Magnesium sterate NF 8 8 8 8 8 8 8 8 8 
 Table Wight: 820 820 820 820 820 820 820 820 820 
 
Pre-Compression Evaluation 
Evaluation of Powder Blends 
1.  Bulk density:  
Bulk density was calculated from the formula given 
below. 
Bulk density (g /ml) =   
Weight  of  the  blend
Bulk  volume  of  the  blend
2. Tapped Density:  
Tapped density was calculated from the formula below. 
Tapped density (g/ml) =  
Weight  of   the  blend
Tapped  volume  of  the  blend
 
3. Measures of Powder Compressibility:  
For poorer flowing materials, there are frequently 
greater inter-particle interactions, and a greater 
difference between the bulk and tapped densities were 
observed. These differences are reflected in the 
compressibility index and Hausner’s ratio. 
Carr’s compressibility index= 
Tapped  denesity −bulk  denesity
Tapped  denesity
×100 
Hausner’s ratio =  
Tapped  denesity
Bulk  denesity
 
Post-Compression Evaluation 
1. Weight variation test:
 5
 
The USP weight variation test is run by weighing 20 
tablets individually, calculating the average weight & 
comparing the individuals tablet weight to the average.  
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2. Thickness and Diameter:
6 
The thickness and diameter of the tablets were 
determined using a thickness gauge Vernier calipers 
model CD-8” CSX (Mitutoyo, New Delhi, India). Five 
tablets from each batch were used, and average values 
were calculated. 
3. Hardness:
7
 
Three tablets of each of the formulations were measured 
in the hardness test. The hardness was examined using a 
Hardness tester model EH-01 (Electrolab). The hardness 
was measured in kg/cm
2
. 
4. Friability:
 8
 
Then percentage friability was then calculated.  
%𝐅 =
(𝐖𝟏 −𝐖𝟐)
𝐖𝟏
×  100 
%F= Percentage friability 
W1= Initial weight of tablets 
W2= Final weight of tablets.  
5. Floating lag time and duration of floating:
9 
Floating characteristics of the prepared formulations 
were determined using USP XXII paddle apparatus 
under sink conditions. 900ml of hydrochloric acid buffer 
pH 1.2 was used as medium and the temperature was 
maintained to 37±0.5ºC thought the study. The time 
between the introduction of tablet and its buoyancy on 
the gastric fluid required for the tablet to float on the 
gastric fluid (floating lag time) and the time during 
which dosages for measurement buoyant (duration of 
floating) were measured. The integrity of the test tablets 
was observed visually during study. 
6. Effect of Hardness on Buoyancy Lag Time
10 
Formulation F1 to F5 was selected to study the effect of 
hardness on buoyancy lag time. The tablets of batch 6 
were compressed at different compression pressures to 
get the hardness of 5kg/cm2, 6kg/cm2, 7kg/cm2, 
8kg/cm2 and 9kg/cm2. The tablets were evaluated for 
buoyancy lag time. The method was same as mentioned 
in determination of lag time.  
7. In-vitro swelling study
11
 
Tablets were weighed individually and placed separately 
in basket of dissolution medium containing hydrochloric 
acid buffer (pH 1.2) solutions 900 ml at 37±0.5°C. At 12 
hours, the tablets were withdrawn from the basket and 
blotted with tissue paper to removed excess surface 
water and the swollen tablets were reweighed on 
analytical balance. Swelling index (SI) of tablets was 
calculated using the following formula:  
% Swelling Index = 
Wet  weight  − Dry  weight
Wet  weight  
× 100 
In – Vitro Drug Release Studies 
In-vitro dissolution studies were carried out in USP 
type-I (Basket) tablet dissolution apparatus using 900ml 
hydrochloric acid buffer pH 1.2 as dissolution media.  
The basket was rotated at 100 rpm and the temperature 
was maintained at 37±0.5°C throughout the study. 
Atprede termined time intervals 10 mL of the samples 
were withdrawn by means of an auto sampler machine 
with a pre filter. The volume withdrawn at each interval 
was replaced with same quantity of fresh dissolution 
medium maintained at 37±0.5°C. The samples were 
analyzed for drug releases by measuring the absorbance 
at 255 nm using HPLC method. 
 
 
RESULTS AND DISCUSSION: 
Particle Size Analysis of Metformin HCl: 
 
Figure 1: Particle size distribution 
 
The flow properties of powders are dependent upon the 
particle size distribution as well as particle shape. 
Asymmetric particles have poor flow characteristics and 
hence granulation techniques are used to convert blends 
of drug and other additives into particles of uniform 
size having good flow properties.  
Keshari et al                                          Journal of Drug Delivery & Therapeutics. 2015; 5(6) 48 
© 2011-15, JDDT. All Rights Reserved                                                   ISSN: 2250-1177                                             CODEN (USA): JDDTAO 
PREPARATION OF STANDARD CURVE OF Metformin HCl  
 
Figure 2: Preparation of Standard Curve of Metformin HCl 
Linearity plot of Metformin HCl in the concentration range of 5-40 µg/ml were evaluated. Linear absorbance versus 
concentration gives regression equation; Y=0.0217x-0.002, with a correlation coefficient (r
2
) of more than 0.99 in 0.1N 
HCl. 
Fourier transform infrared spectroscopy: 
 
Figure 3: FT-IR spectrum standard of Metformin HCl 
Figure 4: FT-IR spectrum of Metformin HCl 
 
Nuclear magnetic resonance spectroscopy:  
 
Figure 5: Nuclear magnetic resonance spectroscopy Ref. STD Metformin HCl 
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Figure 6: Nuclear magnetic resonance spectroscopy Ref. STD Metformin HClMASS 
Mass Spectroscopy of Metformin HCl 
Because of their low stabilities in the ion trap detector, these product ions (m/z=60.4 for Metformin HCl  ) are unsuitable 
for Quantitation of Metformin HCl. Therefore, the isolated precursorions (m/z=130.2 for Metformin HCl  are selected for 
quantitative analysis without any fragmentation. 
Figure 7: Mass Spectroscopy of Metformin HCl 
POWDER X-RAY DIFFRACTOMETRY  
 
Figure 8: X- ray Diffraction graph of Ref. Std Metformin HCl 
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Figure 9: X- ray Diffraction graph of Metformin HCl 
 
X-ray diffraction study of pure drug was carried out and 
its high intensity diffraction peaks at 2θshowed sharp 
peaks as similar to standard Metformin HCl  , both 
PXRD pattern showing crystalline nature as showed in 
figure (8,9). 
Pre-Optimization Studies 
Evaluation of the Metformin HCl: Physical evaluation 
of the Drug  
The API of were tested by various studies including bulk 
density 0.45gm/ml), tapped density 0.56 gm/ml, 
Hausner’s ratio 1.24 and Carr’s index 19.64 %). All the 
results showed very-very poor flow property. 
 
Table 8: Metformin HCl Characterization 
Sr.No Characteristics Results 
1 Physical Appearance Off-White Powder 
2 Bulk Density 0.45 gm/ml 
3 Tap Density 0.74gm/ml 
4 
Carr’s Compressibility 
Index 
38.64 
5 Hausner’s Ratio 1.24 
6 Melting Point 222 to226°C 
 
Pre-Compression Evaluation 
Table 9: Pre-compression parameters for formulations F1-F5 
Sr.No Batch No 
Bulk Density 
(g/ml) 
Tapped Density 
(g/ml) 
Carr’s Index Hausner’s Ratio 
1 F1 0.519 0.65 20 1.25 
2 F2 0.64 0.74 13.51 1.1 
3 F3 0.59 0.71 16.90 1.22 
4 F4 0.25 0.64 19.93 1.24 
5 F5 0.56 0.66 15.06 1.17 
 
Post-Compression Evaluation 
Table 10: Post compression parameters for formulations F1-F5 
Sr.no Formulation code F1 F2 F3 F4 F5 
1 Thickness (mm) 6.45 6.42 6.82 5.12 5.75 
2 Hardness (Kg/cm
2 
) 13.5 15.5 14.6 13.9 13.5 
3 Friability (%) 0.742 0.234 0.342 0.782 0.740 
4 Weight Variation (mg) 0.12 0.34 0.56 0.54 0.67 
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Floating Lag Time and Duration Of Floating  
 
Figure 10: Floating lag time of various formulations 
 
                            
    (a) At Initial Time                                                       (b) After 50 Seconds 
                               
(c) After 70 Seconds                                                     (d) After 12 hours 
Figure 11: (a, b, c, d): Determination of Floating Time and Floating Lag Time 
Studies to determine the Floating lag time and duration 
of floating of various formulations were carried out and 
the result indicated that floating lag time for all the 
tablets was within 0-4 minute after immersion into 
gastric media and duration of floating was greater than 
12 hours for all batches. The effect of hardness on 
buoyancy lag time was studied and results indicated that 
with increasing the hardness, lag time also increased. 
 
Figure 12: Effects of hardness on buoyancy lag time 
F1 F2 F3 F4 F5
Floating lag time (sec) 70 0 50 60 80
Duration of floating (hours) 12 0 12 12 12
0
20
40
60
80
100
Floating lag time
0
50
100
150
11.5 12.5 14 15.1 I6.6
Buoyancy lag time (seconds)
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IN VITRO DISSOLUTION TEST 
The dissolution profile of all batches (F1 to F5) Prepared by High Shear Mixer Granulator and Marketed formulation in 
hydrochloric acid (1.2 pH) and results are reported in following tables: 
 
Figure 13: Specimen Chromatogram of Metformin HCl Standard 
 
Figure 14: In-vitro drug release profiles graph 
Prototype gastroretentive formulation Prepared by High Shear Mixer Granulator and Marketed extended release 
formulation in hydrochloric acid (1.2 pH) compared and it was realized that formulation F5 shown similar release profile 
as compared to others. Coated F2 formulation profile was much slower at initial time point therefore coating technique 
was discouraged further optimization.   
DOE OPTIMIZATION BY 3
2
 CENTRAL COMPOSITE DESIGN 
PRE-COMPRESSION EVALUATION 
Table 11: Pre-compression parameters for formulations F1-F9 
Sr.No Batch No 
Bulk Density 
(g/ml) 
Tapped Density 
(g/ml) 
Carr’s Index Hausner’s Ratio 
1 F1 0.473 0.602 21 1.27 
2 F2 0.551 0.674 18.24 1.22 
3 F3 0.483 0.59 18.13 1.22 
4 F4 0.491 0.619 20.67 1.26 
5 F5 0.49 0.61 19.67 1.24 
6 F6 0.514 0.593 13.32 1.15 
7 F7 0532 0.633 15.48 1.18 
8 F8 0.56 0.627 10.68 1.11 
9 F9 0.457 0.549 16.45 1.20 
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Floating Lag Time and Duration Of Floating 
 
Figure 15: Determination of Floating Time and Floating Lag Time 
Studies to determine the Floating lag time and duration of floating of various formulations were carried out and the 
results indicated that floating lag time which was observed for all the tablets was within 0-4 minute after immersion into 
gastric media and duration of floating was greater than 12 hours for all batches. 
 In Vitro Dissolution Test: The dissolution profile of all batches (F1 to F9) Prepared for DOE optimization and 
Marketed formulation in hydrochloric acid (1.2 pH) and results are reported in following tables. 
 
Figure 16: In-vitro drug release profiles of various formulations (F1 to F9 and MKT formulation) 
Dissolution profile of DOE optimized gastroretentive formulation (F1-F9) and Marketed extended release formulation in 
hydrochloric acid (1.2 pH) compared and it was realized that all formulation (F1-F9)  shown similar release profile as 
compared with Marketed extended release formulation, hence out of all formulation composition any of formulation can 
be chosen for further commercial scalability and  production. From DOE optimization it also proves robustness range of 
process.  
Assay (BY HPLC) OF Metformin HCl Tablets 
Table 12: Assay (By HPLC) of Metformin HCl Tablets 
Sr.no Formulation Area % Assay 
1 F1 2045019 99.10 
2 F2 1966006 95.27 
3 F3 1970934 95.51 
4 F4 1982262 96.06 
5 F5 2063604 100.00 
6 F6 1862677 90.26 
7 F7 1918276 92.96 
8 F8 1953795 94.64 
9 F9 2072338 100.42 
 
F1 F2 F3 F4 F5 F6 F7 F8 F9
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F7 500 mg
F8 500 mg
F9 500 mg
MKT 500 mg
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Average standard – 2063511.6 
Assay result of all formulation were observed in between (90 to 110%) of range. 
 SELECTION OF THE OPTIMIZED FORMULATION 
The optimized formulation was selected by trading off the various responses. Fig.17 
 Depicts the overlay plot showing the location of the optimized formulation. 
 
Figure 17: Selection of the optimized formulation 
In vitro dissolution test of final formulation:  
 
Figure 18:  In-vitro drug release profiles of final formulation 
Accelerated stability study of optimization formulation batch 
 
Figure 19: Specimen Chromatogram of Metformin HCl Standard 
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Figure 20: In-Vitro Drug release Stability studies 
There is no significant fall observed in drug release 
profile of formulation F9 compared in initial and 3 
month accelerated stability condition.  
CONCLUSION 
The main aim of the present dissertation was to develop 
novel Floating extended release formulation of 
Metformin HCl which is targeted to release drug till 12 
hours at gastric region and compared the in-vitro 
similarity of novel formulation with already existing 
Marketed extended release formulation of Metformin 
HCl, which releases drug in intestinal region. Thus from 
the data obtained, it can be concluded that:   
Gastroretentive dosage form of an antidiabetic drug of 
Metformin HCl formulated as an approach to increase 
gastric residence time and thereby minimizing hepatic 
extraction ratio followed by dangerous side effects. It 
was an effort to introduced sodium bicarbonate as 
effervescent agent in matrix based tablet, which tends to 
create buoyancy in formulation at gastric site, results 
tablet start floating in gastric region for sustained time 
period, thus release of drug at site of gastric mucosa in 
sustained way. Among the polymers used to improve the 
gastric residence, cellulose Polymers HPMC K100M, 
HPMC K200CR, showed better control over drug 
release than Carbopol 941P. Gastroretentive dosage 
form (Novel extended release formulation) are claiming 
to advantage to reduce dosing frequency over 
conventionally available IR formulation of 500 mg , 850 
mg and 1000 mg recommended to two to three times 
daily leads to multiple dosing and patient incompliance 
as well as Potential side effects. Gastroretentive dosage 
form (Novel extended release formulation) is claiming 
to enhanced bioavailability and absorption of drug at 
site of gastric region. 
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